LYEL
Lyell Immunopharma, Inc. · Healthcare · Market cap $364.1M
Insiders bought $49.8M net in the last 90 days ·6 sellers, 2 buyers· latest Form 4 filed Nov 5, 2026
Insider Buying
$75.0M
reported purchases (SEC code P)
Insider Selling
$608K
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Latest filing
Nov 5, 2026
ARCH Venture Partners IX, LLC
Lyell Immunopharma, Inc. (LYEL) has 36 SEC Form 4 filings (41 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Nov 5, 2026.
Inside the rolling window, 9 insiders at Lyell Immunopharma, Inc. reported 4 open-market purchases totaling $75.0M and 29 open-market sales totaling $608K. The most active filer is Chief Scientific Officer Lee Gary K. with 6 filings. Insiders have net bought $49.7M over the trailing 6 months. The largest single insider purchase in this window was $25.0M by 10% Owner ARCH Venture Partners IX, LLC on Nov 4, 2026.
- Industry:Biotechnology
- CEO:Lynn Seely
- Employees:161
- HQ:South San Francisco, CA, US
- IPO:2021-06-17
| Source | |||||||
|---|---|---|---|---|---|---|---|
ARCH Venture Partners IX, LLCFirst in 8 months | 10% Owner | Purchase | 2,321,262 | $25.0M | Nov 5 | -0.9% | SEC ↗ |
ARCH Venture Fund XIII, L.P.First in 8 months | 10% Owner | Purchase | 2,321,262 | $25.0M | Nov 5 | -0.9% | SEC ↗ |
Aguirre Jarrad MattieuFirst filing | Chief Medical Officer | Sale | 422 | $4K | Oct 13 | +97.9% | SEC ↗ |
Shook DavidFirst in 3 months | Chief Medical Officer | Sale | 500 | $6K | Sep 10 | +21.8% | SEC ↗ |
| Chief Scientific Officer | Sale | 1,457 | $23K | Aug 25 | -4.1% | SEC ↗ | |
| Chief Operating Officer | Sale | 989 | $15K | Aug 25 | -4.1% | SEC ↗ | |
| President and CEO | Sale | 9,589 | $149K | Aug 25 | -4.1% | SEC ↗ | |
| Chief Scientific Officer | Sale | 131 | $2K | Aug 11 | +4.9% | SEC ↗ | |
| President and CEO | Sale | 390 | $6K | Aug 11 | +4.9% | SEC ↗ | |
| VP, Corporate Controller | Sale | 621 | $9K | Aug 11 | +4.9% | SEC ↗ | |
| Chief Operating Officer | Sale | 89 | $1K | Aug 11 | — | SEC ↗ | |
| 10% Owner | Sale | 10 | $137 | Jul 20 | — | SEC ↗ | |
Innovative Cellular Therapeutics Holdings LtdFirst filing | 10% Owner | Sale | 10 | $137 | Jul 18 | — | SEC ↗ |
Seely LynnFirst in 4 months | President and CEO | Sale | 388 | $7K | Jun 15 | — | SEC ↗ |
Lee Gary K.First in 4 months | Chief Scientific Officer | Sale | 130 | $2K | Jun 15 | — | SEC ↗ |
Hill Stephen J.First in 4 months | Chief Operating Officer | Sale | 89 | $2K | Jun 15 | — | SEC ↗ |
Bulis Veronica SanchezFirst in 4 months | VP, Corporate Controller | Sale | 217 | $4K | Jun 15 | — | SEC ↗ |
Shook DavidFirst filing | Chief Medical Officer | Sale | 1,977 | $25K | Jun 11 | — | SEC ↗ |
ARCH Venture Partners IX, LLCFirst filing | 10% Owner | Purchase | 488,090 | $12.5M | Mar 9 | — | SEC ↗ |
ARCH Venture Fund XIII, L.P.First filing | 10% Owner | Purchase | 488,090 | $12.5M | Mar 9 | — | SEC ↗ |
| Chief Operating Officer | Sale | 1,236 | $29K | Feb 12 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 1,671 | $39K | Feb 12 | — | SEC ↗ | |
| President and CEO | Sale | 7,455 | $174K | Feb 12 | — | SEC ↗ | |
Hill Stephen J.First in 3 months | Chief Operating Officer | Sale | 109 | $3K | Feb 11 | — | SEC ↗ |
Seely LynnFirst in 3 months | President and CEO | Sale | 438 | $10K | Feb 11 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does LYEL have?
Lyell Immunopharma, Inc. (LYEL) has 36 SEC Form 4 filings (41 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Nov 5, 2026.
When was the most recent SEC Form 4 filing for LYEL?
The most recent Form 4 filing for LYEL on Tracefour is dated Nov 5, 2026.
Who is the most active insider at LYEL?
The most active SEC Form 4 filer at LYEL in the rolling window is Chief Scientific Officer Lee Gary K., with 6 filings.
What is the net insider flow at LYEL over the last 6 months?
Over the trailing 180 days, insiders at LYEL have net bought $49.7M based on SEC Form 4 disclosures.
What was the largest insider purchase at LYEL?
The largest single insider open-market purchase at LYEL in the rolling window was $25.0M by 10% Owner ARCH Venture Partners IX, LLC on 2026-11-04.
What is the total insider buy and sell value at LYEL in the current window?
Inside the rolling window, insiders at LYEL bought $75.0M and sold $608K based on SEC Form 4 filings.
Can I get alerts for LYEL insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Lyell Immunopharma, Inc. (LYEL). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Lyell Immunopharma, Inc. is in the Healthcare sector.